- |||||||||| STM418 / STCube Pharma
Journal: Targeting glycosylated PD-1 induces potent anti-tumor immunity. (Pubmed Central) - Nov 14, 2020
The monoclonal antibody STM418 specifically targeted glycosylated PD-1, exhibiting higher binding affinity to PD-1 than FDA-approved PD-1 antibodies, potently inhibiting PD-L1/PD-1 binding, and enhancing anti-tumor immunity. Together these findings provide novel insights into the functional significance of PD-1 glycosylation and offer a rationale for targeting glycosylated PD-1 as a potential strategy for immunotherapy.
- |||||||||| STM418 / STCube Pharma
[VIRTUAL] Targeting glycosylated PD-1 induces potent anti-tumor immunity (Virtual Meeting II: E-Posters) - May 16, 2020 - Abstract #AACRII2020AACR-II_4529;
A monoclonal antibody that specifically targets glycosylated PD-1, STM418, exhibits higher binding affinity to PD-1 than FDA-approved PD-1 antibodies, potently inhibits PD-L1/PD-1 binding, and enhances anti-tumor immunity. Our findings provide novel insights into the functional significance of PD-1 glycosylation and offer a rationale for targeting glycosylated PD-1 as a potential strategy for immunotherapy.
|
